Back to Cardiology
Cardiologyv2016Evidence-Based

Dual Antiplatelet Therapy (DAPT) Score

Predicts which patients will benefit from prolonged DAPT after coronary stent placement. Developed from the DAPT Study randomized trial to predict combined ischemic and bleeding risk for patients being considered for continued thienopyridine therapy beyond 1 year.

Clinical Input Parameters

years
Range: 18 — 120 years
Clinical Assessment
Awaiting Parameters
dapt score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Dual Antiplatelet Therapy (DAPT) Score is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within cardiology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

DAPT Score = Age points + Clinical factors. Age: 65-75 years (-1 pt), ≥75 years (-2 pts). Positive factors: Diabetes (+1 pt), Current smoking (+1 pt), Prior MI/PCI (+1 pt), Stent diameter <3mm (+1 pt), CHF/LVEF <30% (+2 pts), Vein graft PCI (+2 pts), Paclitaxel-eluting stent (-1 pt), MI at presentation (+1 pt).

Clinical Pearls & Practice Notes

  • Developed from the DAPT Study randomized trial data with 11,648 patients.
  • Score ranges from approximately -2 to +10 points.
  • Score ≥2 indicates favorable benefit/risk ratio for prolonged DAPT beyond 12 months.
  • Score <2 indicates unfavorable benefit/risk ratio for prolonged DAPT.
  • Age 65-75 years: -1 point, Age ≥75 years: -2 points, Age <65 years: 0 points.
  • Diabetes mellitus: +1 point, Current cigarette smoking: +1 point.
  • Prior MI or prior PCI: +1 point, Stent diameter <3 mm: +1 point.
  • CHF or LVEF <30%: +2 points, Saphenous vein graft PCI: +2 points.
  • Paclitaxel-eluting stent: -1 point, MI at presentation: +1 point.
  • High scores (≥2) predict high ischemic risk and low bleeding risk.
  • Low scores (<2) predict high bleeding risk and low ischemic risk.
  • Should be used in conjunction with clinical judgment and patient preferences.
  • Consider individual bleeding and ischemic risk factors not captured in the score.
  • Applies to patients who have completed 12 months of DAPT without major events.

Evidence & Literature Citations

  1. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SLT, Gershlick AH, Cohen DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016;315(16):1735-49. doi: 10.1001/jama.2016.3775.
  2. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Circulation. 2016;134(10):e123-55. doi: 10.1161/CIR.0000000000000404.
  3. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025-1034. doi: 10.1016/S0140-6736(17)30397-5.

Score Interpretation Ranges

Low Score (<2)-10 – 1 pts

Unfavorable benefit/risk ratio

High Score (≥2)2 – 20 pts

Favorable benefit/risk ratio

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.